Noxopharm (ASX:NOX)
Delivering Science. Transforming Lives
Learn more

UPCOMING EVENTS

Noxopharm 2021 AGM

SHARE PRICE

Mkt Cap:
(20 minutes delay)
Noxopharm is pioneering life-changing therapies through innovative science.
NOXOPHARM & VEYONDA
Noxopharm's drug development pipelines is focused on developing new treatment options for a broad range of solid tumour cancers and septic shock. Both areas of unmet medical needs.
Noxopharm's current lead drug candidate is Veyonda®, currently being tested in several cancer trials, and also in at-risk COVID-19 patients, for its ability to harness the power of the immune system.
LATEST ASX ANNOUNCEMENTS
FOUR R&D BUSINESSES IN ONE COMPANY
Cancer Research
Pipeline
Veyonda®
 

Noxopharm History

Noxopharm, an Australian drug discovery and development company, was founded in 2015 by Dr Graham Kelly, whose lifetime of scientific research in the unique isoflavonoid biotechnology platform led him to establishing his third public company.